ABOUT PAREXEL INTERNATIONAL
Parexel is a leading global clinical development partner providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 22,000+ global employees work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart®. We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award for advancing the clinical research profession through strong site partnerships. For more information, visit parexel.com and follow us on LinkedIn, X, Facebook and Instagram.
SOLUTIONS
CONTACT INFORMATION
Parexel International
541 Church at North Hills St., Suite 1000
Raleigh, NC 27609
UNITED STATES
INDUSTRY INSIGHTS
-
![LSC Content Images]( "Executing Pediatric Gene Therapy Trials At The Site Level")
Pediatric gene therapy trials demand exceptional coordination at the site level, and these frontline insights can help you manage protocol complexity and balance operations with family‑centered care.
-
![Parexel_PaidADs_HighRes]( "Navigating The Challenges Of Large, International Phase III Breast Cancer Trials")
In the competitive landscape of breast cancer research, aligning biomarker testing, regulatory pathways, and regional operations from day one creates a path to faster enrollment and stronger outcomes.
-
![0004_EU---two-women-sitting-at-an-outdoor-cafe-1-(high-res)]( "Rethinking Patient Representation In Breast Cancer Trials For Better Outcomes")
Broad patient representation in breast cancer trials is critical, and inclusive trial design improves data relevance, accelerates enrollment, and supports global approval and access.
-
![Faster Starts, Stronger Finish Operational Excellence In NSCLC]( "Faster Starts, Stronger Finish: Operational Excellence In NSCLC")
In NSCLC trials, data‑driven site selection, streamlined protocols, efficient screening strategies, and proactive engagement can accelerate enrollment and improve trial efficiency across regions.
-
![How Adaptive Design Accelerates Early Phase NSCLC Development]( "How Adaptive Design Accelerates Early‑Phase NSCLC Development")
Adaptive trial designs and an adaptive mindset enable non-small cell lung cancer (NSCLC) sponsors to optimize dose, respond to evolving expectations, and accelerate early‑phase development.
-
![June 8 Parexel eBlast Image resize]( "Timing And Data Are Critical To Winning BTD For Rare Disease Drugs")
Breakthrough Therapy designation (BTD) can accelerate rare disease drug development—but timing and evidence are everything. Learn how to position your program for FDA success.
-
![Delivering Complex Oncology Trials At Scale]( "Delivering Complex Oncology Trials At Scale")
Parexel delivered two complex, global Phase III prostate cancer trials by aligning site selection, logistics, imaging workflows, and RAM regulatory expertise—achieving faster enrollment and on‑time execution.
-
![Malaysia - care worker with patient in a wheelchair (high res)]( "Strategies To Win Breakthrough Designation In Rare Disease Programs")
Breakthrough designation can unlock faster paths for rare disease therapies. Learn how smart timing, compelling evidence, and early regulatory alignment can turn promising science into accelerated patient impact.
-
![Female patient consults with an HCP during in-home visit (high res)]( "5 Strategies For Designing Successful Complex Rare Disease Trials")
Rare disease trials demand inventive design. Uncover creative strategies that help sponsors overcome tiny populations, complex endpoints, and operational hurdles to advance meaningful breakthroughs.
-
![APAC - elderly woman gets help from her daughter with her cap (high res)]( "5 RWE Approaches That Strengthen Precision Oncology")
Real-world evidence is becoming vital in precision oncology. Discover five creative, practical ways sponsors can use RWE to fuel development, sharpen regulatory strategy, and strengthen market access.
-
![Elderly oncology patient at her window (high res)]( "Accelerating Oncology Drug Development Through Innovative Designs")
Adaptive and novel trial designs are redefining oncology development, powering faster decisions with smarter flexibility. Discover innovative approaches that elevate efficiency while safeguarding scientific rigor.
-
![Senior patient gazing out window in hospital room (high res)]( "Mastering Precision Oncology Start-Up: Reducing Screening Delays")
Biomarker-driven trials create intricate screening hurdles. Explore creative, practical ways to accelerate start‑up, boost enrollment, and power precision oncology studies forward with greater speed.
